Hypoxia in astrocytic tumors and implications for therapy

Neurobiology of Disease

Volumn 85, Issue , 2016, Pages 227-233

  Cavazos, David A ^a   Brenner, Andrew J ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

Author keywords

Acetate; Aerobic glycolysis; Astrocytic tumors; CXCL12; CXCR7; Glioblastoma multiforme; Hypoxia; Metabolic derangement; Pseudopalisading necrosis; TH 302

Indexed keywords

BEVACIZUMAB; CEDIRANIB; CHEMOKINE RECEPTOR CXCR4; DNA; EVOFOSFAMIDE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; STROMAL CELL DERIVED FACTOR 1; SUNITINIB; VASCULOTROPIN;

ASTROCYTOMA; BLOOD BRAIN BARRIER; BRAIN HYPOXIA; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DRUG TARGETING; GLIOBLASTOMA; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; BRAIN NEOPLASMS; HYPOXIA; PATHOPHYSIOLOGY;

ANIMALS; ASTROCYTOMA; BRAIN NEOPLASMS; HUMANS; HYPOXIA;

EID: 84949727975     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.06.007     Document Type: Review

References (62)

1. Amberger-Murphy V. Hypoxia helps glioma to fight therapy. Curr. Cancer Drug Targets 2009, 9(3):381-390.
2. Bakondi B., Shimada I.S., Peterson B.M., Spees J.L. Stromal-derived factor 1 alpha secreted by human CD133-derived multipotent stromal cells promotes neural progenitor cell survival through CXCR7. Stem Cells Dev. 2011, 20(6):1021-1029.
3. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., Kozak K.R., Cahill D.P., Chen P.J., Zhu M., Ancukiewicz M., Mrugala M.M., Plotkin S., Drappatz J., Louis D.N., Ivy P., Scadden D.T., Benner T., Loeffler J.S., Wen P.Y., Jain R.K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11(1):83-95.
4. Benedetti E., Galzio R., Laurenti G., D'Angelo B., Melchiorre E., Cifone M.G., Fanelli F., Muzi P., Coletti G., Alecci M., Sotgiu A., Ceru M.P., Cimini A. Lipid metabolism impairment in human gliomas: expression of peroxisomal proteins in human gliomas at different grades of malignancy. Int. J. Immunopathol. Pharmacol. 2010, 23(1):235-246.
5. Boimel P.J., Smirnova T., Zhou Z.N., Wyckoff J., Park H., Coniglio S.J., Qian B.Z., Stanley E.R., Cox D., Pollard J.W., Muller W.J., Condeelis J., Segall J.E. Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast Cancer Res. 2012, 14(1):R23.
6. Brat D.J., Castellano-Sanchez A.A., Hunter S.B., Pecot M., Cohen C., Hammond E.H., Devi S.N., Kaur B., Van Meir E.G. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res. 2004, 64(3):920-927.
7. Brenner A.J., Floyd J., Eng C., Kroll S., Fichtel L., Gruslova A., Lodi A., Tiziani S. Phase 1/2 study of TH-302, investigational hypoxia-activated prodrug, and bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma. Neuro Oncol. 2014, 16(S5).
8. Burger P.C., Green S.B. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 1987, 59(9):1617-1625.
9. Cartier L., Hartley O., Dubois-Dauphin M., Krause K.H. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res. Brain Res. Rev. 2005, 48(1):16-42.
10. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., Capla J.M., Galiano R.D., Levine J.P., Gurtner G.C. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 2004, 10(8):858-864.
11. Chen C., Pore N., Behrooz A., Ismail-Beigi F., Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 2001, 276(12):9519-9525.
12. Denham J.W., Hauer-Jensen M. The radiotherapeutic injury-a complex 'wound'. Radiother. Oncol. 2002, 63(2):129-145.
13. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegue E., Song H., Vandenberg S., Johnson R.S., Werb Z., Bergers G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13(3):206-220.
14. Ebos J.M., Lee C.R., Christensen J.G., Mutsaers A.J., Kerbel R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(43):17069-17074.
15. Friedman H.S., Prados M.D., Wen P.Y., Mikkelsen T., Schiff D., Abrey L.E., Yung W.K., Paleologos N., Nicholas M.K., Jensen R., Vredenburgh J., Huang J., Zheng M., Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009, 27(28):4733-4740.
16. Ganjoo K.N., Cranmer L.D., Butrynski J.E., Rushing D., Adkins D., Okuno S.H., Lorente G., Kroll S., Langmuir V.K., Chawla S.P. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Oncology 2011, 80(1-2):50-56.
17. Hattermann K., Mentlein R., Held-Feindt J. CXCL12 mediates apoptosis resistance in rat C6 glioma cells. Oncol. Rep. 2012, 27(5):1348-1352.
18. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352(10):997-1003.
19. Hitosugi T., Kang S., Vander Heiden M.G., Chung T.W., Elf S., Lythgoe K., Dong S., Lonial S., Wang X., Chen G.Z., Xie J., Gu T.L., Polakiewicz R.D., Roesel J.L., Boggon T.J., Khuri F.R., Gilliland D.G., Cantley L.C., Kaufman J., Chen J. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2009, 2(97):ra73.
20. Hou L.C., Veeravagu A., Hsu A.R., Tse V.C. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg. Focus. 2006, 20(4):E5.
21. Howlader N., Noone A., Krapcho M., Garshel l.J., Miller D., Altekruse S., Kosary C., Yu M., Ruhl J., Tatalovich Z., Mariotto A., Lewis D., Chen H., Feuer E., Cronin K. SEER Cancer Statistics Review 2014, 1975-2011.
22. Iwamoto F.M., Abrey L.E., Beal K., Gutin P.H., Rosenblum M.K., Reuter V.E., DeAngelis L.M., Lassman A.B. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009, 73(15):1200-1206.
23. Jain R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 2013, 31(17):2205-2218.
24. Kaelin W.G., McKnight S.L. Influence of metabolism on epigenetics and disease. Cell 2013, 153(1):56-69.
25. Keunen O., Johansson M., Oudin A., Sanzey M., Rahim S.A., Fack F., Thorsen F., Taxt T., Bartos M., Jirik R., Miletic H., Wang J., Stieber D., Stuhr L., Moen I., Rygh C.B., Bjerkvig R., Niclou S.P. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(9):3749-3754.
26. Kunkel P., Ulbricht U., Bohlen P., Brockmann M.A., Fillbrandt R., Stavrou D., Westphal M., Lamszus K. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 2001, 61(18):6624-6628.
27. Laurenti G., Benedetti E., D'Angelo B., Cristiano L., Cinque B., Raysi S., Alecci M., Ceru M.P., Cifone M.G., Galzio R., Giordano A., Cimini A. Hypoxia induces peroxisome proliferator-activated receptor alpha (PPARalpha) and lipid metabolism peroxisomal enzymes in human glioblastoma cells. J. Cell. Biochem. 2011, 112(12):3891-3901.
28. Long P.M., Tighe S.W., Driscoll H.E., Fortner K.A., Viapiano M.S., Jaworski D.M. Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest. J. Cell. Physiol. 2015, 230(8):1929-1943.
29. Lucio-Eterovic A.K., Piao Y., de Groot J.F. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin. Cancer Res. 2009, 15(14):4589-4599.
30. Lyssiotis C.A., Cantley L.C. Acetate fuels the cancer engine. Cell 2014, 159(7):1492-1494.
31. Mannino M., Chalmers A.J. Radioresistance of glioma stem cells: intrinsic characteristic or property of the 'microenvironment-stem cell unit'?. Mol. Oncol. 2011, 5(4):374-386.
32. Mashimo T., Pichumani K., Vemireddy V., Hatanpaa K.J., Singh D.K., Sirasanagandla S., Nannepaga S., Piccirillo S.G., Kovacs Z., Foong C., Huang Z., Barnett S., Mickey B.E., DeBerardinis R.J., Tu B.P., Maher E.A., Bachoo R.M. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 2014, 159(7):1603-1614.
33. Mason R.P., Hunjan S., Le D., Constantinescu A., Barker B.R., Wong P.S., Peschke P., Hahn E.W., Antich P.P. Regional tumor oxygen tension: fluorine echo planar imaging of hexafluorobenzene reveals heterogeneity of dynamics. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42(4):747-750.
34. Mendez O., Zavadil J., Esencay M., Lukyanov Y., Santovasi D., Wang S.C., Newcomb E.W., Zagzag D. Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol. Cancer 2010, 9:133.
35. Meng F., Evans J.W., Bhupathi D., Banica M., Lan L., Lorente G., Duan J.X., Cai X., Mowday A.M., Guise C.P., Maroz A., Anderson R.F., Patterson A.V., Stachelek G.C., Glazer P.M., Matteucci M.D., Hart C.P. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302 2015, Mol. Cancer Ther.
36. Miao Z., Luker K.E., Summers B.C., Berahovich R., Bhojani M.S., Rehemtulla A., Kleer C.G., Essner J.J., Nasevicius A., Luker G.D., Howard M.C., Schall T.J. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(40):15735-15740.
37. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410(6824):50-56.
38. Murdoch C. CXCR4: chemokine receptor extraordinaire. Immunol. Rev. 2000, 177:175-184.
39. Onnis B., Rapisarda A., Melillo G. Development of HIF-1 inhibitors for cancer therapy. J. Cell. Mol. Med. 2009, 13(9A):2780-2786.
40. Ostrom Q.T., Gittleman H., Liao P., Rouse C., Chen Y., Dowling J., Wolinsky Y., Kruchko C., Barnholtz-Sloan J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014, 16(4).
41. Ostrom Q.T., Gittleman H., Liao P., Rouse C., Chen Y., Dowling J., Wolinsky Y., Kruchko C., Barnholtz-Sloan J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014, 16(Suppl. 4):iv1-iv63.
42. Poulos A., Beckman K., Johnson D.W., Paton B.C., Robinson B.S., Sharp P., Usher S., Singh H. Very long-chain fatty acids in peroxisomal disease. Adv. Exp. Med. Biol. 1992, 318:331-340.
43. Raleigh J.A., Koch C.J. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem. Pharmacol. 1990, 40(11):2457-2464.
44. Raleigh J.A., Chou S.C., Bono E.L., Thrall D.E., Varia M.A. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49(2):569-574.
45. Rong Y., Durden D.L., Van Meir E.G., Brat D.J. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J. Neuropathol. Exp. Neurol. 2006, 65(6):529-539.
46. Sankhala K.K., Chiorean E.G., Armstrong A.J., Borad M.J., Traynor A.M., Gadgeel S.M., Langmuir V.K., Eng C., Kroll S., Burris H. Phase I/II study of TH-302 in combination with docetaxel in patients with solid tumors including NSCLC and castrate-resistant prostate cancer (CRPC). 2010 ASCO Annual Meeting. J. Clin. Oncol. 2010, 28. (suppl; abstr e13527).
47. Sathornsumetee S., Cao Y., Marcello J.E., Herndon J.E., McLendon R.E., Desjardins A., Friedman H.S., Dewhirst M.W., Vredenburgh J.J., Rich J.N. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol. 2008, 26(2):271-278.
48. Schelman W.R. Phase I/II study of TH-302 in combination with gemcitabine in patients with solid tumors including advanced pancreatic cancer. 2010 ASCO Annual Meeting. J. Clin. Oncol. 2010, (suppl; abstr e13519).
49. Singh I. Mammalian peroxisomes: metabolism of oxygen and reactive oxygen species. Ann. N. Y. Acad. Sci. 1996, 804:612-627.
50. Spence A.M., Muzi M., Swanson K.R., O'Sullivan F., Rockhill J.K., Rajendran J.G., Adamsen T.C., Link J.M., Swanson P.E., Yagle K.J., Rostomily R.C., Silbergeld D.L., Krohn K.A. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin. Cancer Res. 2008, 14(9):2623-2630.
51. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352(10):987-996.
52. Taal W., Oosterkamp H.M., Walenkamp A.M., Dubbink H.J., Beerepoot L.V., Hanse M.C., Buter J., Honkoop A.H., Boerman D., de Vos F.Y., Dinjens W.N., Enting R.H., Taphoorn M.J., van den Berkmortel F.W., Jansen R.L., Brandsma D., Bromberg J.E., van Heuvel I., Vernhout R.M., van der Holt B., van den Bent M.J. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014, 15(9):943-953.
53. Tran P.B., Banisadr G., Ren D., Chenn A., Miller R.J. Chemokine receptor expression by neural progenitor cells in neurogenic regions of mouse brain. J. Comp. Neurol. 2007, 500(6):1007-1033.
54. Vander Heiden M.G., Lunt S.Y., Dayton T.L., Fiske B.P., Israelsen W.J., Mattaini K.R., Vokes N.I., Stephanopoulos G., Cantley L.C., Metallo C.M., Locasale J.W. Metabolic pathway alterations that support cell proliferation. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:325-334.
55. Vlahovic G., Infante J.R., Mita A.C., Traynor A.M., Molina J.R., Lacouture M.E., Langmuir V.K., Eng C., Kroll S., Borad M.J. Phase I/II study of TH-302 in combination with pemetrexed in patients with solid tumors including NSCLC. 2010 ASCO Annual Meeting 2010.
56. Walters M.J., Ebsworth K., Berahovich R.D., Penfold M.E., Liu S.C., Al Omran R., Kioi M., Chernikova S.B., Tseng D., Mulkearns-Hubert E.E., Sinyuk M., Ransohoff R.M., Lathia J.D., Karamchandani J., Kohrt H.E., Zhang P., Powers J.P., Jaen J.C., Schall T.J., Merchant M., Recht L., Brown J.M. Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats. Br. J. Cancer 2014, 110(5):1179-1188.
57. Wang J., Shiozawa Y., Wang J., Wang Y., Jung Y., Pienta K.J., Mehra R., Loberg R., Taichman R.S. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J. Biol. Chem. 2008, 283(7):4283-4294.
58. Ward J.F. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog. Nucleic Acid Res. Mol. Biol. 1988, 35:95-125.
59. Weiss G.J., Infante J.R., Chiorean E.G., Borad M.J., Bendell J.C., Molina J.R., Tibes R., Ramanathan R.K., Lewandowski K., Jones S.F., Lacouture M.E., Langmuir V.K., Lee H., Kroll S., Burris H.A. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin. Cancer Res. 2011, 17(9):2997-3004.
60. Xu L., Duda D.G., di Tomaso E., Ancukiewicz M., Chung D.C., Lauwers G.Y., Samuel R., Shellito P., Czito B.G., Lin P.C., Poleski M., Bentley R., Clark J.W., Willett C.G., Jain R.K. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res. 2009, 69(20):7905-7910.
61. Zagzag D., Esencay M., Mendez O., Yee H., Smirnova I., Huang Y., Chiriboga L., Lukyanov E., Liu M., Newcomb E.W. Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am. J. Pathol. 2008, 173(2):545-560.
62. Zhu A.X., Sahani D.V., Duda D.G., di Tomaso E., Ancukiewicz M., Catalano O.A., Sindhwani V., Blaszkowsky L.S., Yoon S.S., Lahdenranta J., Bhargava P., Meyerhardt J., Clark J.W., Kwak E.L., Hezel A.F., Miksad R., Abrams T.A., Enzinger P.C., Fuchs C.S., Ryan D.P., Jain R.K. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 2009, 27(18):3027-3035.